XSDR:LSE:LSE-Xtrackers MSCI Europe Health Care ESG Screened UCITS ETF 1C (GBX)

ETF | Others |

Last Closing

USD 19399

Change

+193.00 (+1.00)%

Market Cap

USD 0.14B

Volume

227.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

-74.00 (-0.92%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

-422.00 (-5.44%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

-1.25 (-0.66%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+3.60 (+0.40%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.27 (-1.53%)

USD 617.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.16 (-1.14%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

-27.50 (-1.33%)

USD 320.04B
0QZK:LSE Coca-Cola Co.

+1.10 (+1.76%)

USD 266.08B
0QZO:LSE 0QZO

-0.30 (-0.28%)

USD 258.54B

ETFs Containing XSDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.80% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.80% 83% B 77% C+
Trailing 12 Months  
Capital Gain 8.05% 53% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.05% 52% F 58% F
Trailing 5 Years  
Capital Gain 66.57% 83% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.57% 81% B- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 8.33% 66% D+ 69% C-
Dividend Return 8.33% 66% D+ 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.59% 80% B- 90% A-
Risk Adjusted Return 126.42% 100% F 100% F
Market Capitalization 0.14B 51% F 44% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike